All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyDavid R. Nelson, William R. Harlan, Reem Ghalib et al.|Hepatology|2015Cited by 689
Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B<i>gag/pol/nef</i>Vaccine in Healthy AdultsFrances Priddy, Deborah D. Brown, James G. Kublin et al.|Clinical Infectious Diseases|2008Cited by 246
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
High dose oral ganciclovir treatment for cytomegalovirus retinitisJacob Lalezari, Charles A. Robinson, Dorothy N. Friedberg et al.|Journal of Clinical Virology|2002Cited by 45
60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTIONMark Sulkowski, Gerhard Steinmann, E. Ceasu et al.|Journal of Hepatology|2011Cited by 39